ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has closed the previously announced public offering of 10,000,000 shares of its common stock; including 1,500,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offered by AVANIR Pharmaceuticals, Inc. The net proceeds to AVANIR from the sale of shares in this offering, after deducting underwriting discounts and commissions, were approximately $26.6 million.
